…
Curaleaf Holdings, Inc. engages in the retail and wholesale of cannabis products in the United States and internationally. The company operates licensed cultivation; and pharma-grade cannabis processing and manufacturing facilities. It also supplies cannabis on a wholesale basis to Australia, New Zealand, the United Kingdom and various European countries, including Germany, Italy, Poland, the Czech Republic, Switzerland, Sweden and Norway. In addition, the company operates a medical cannabis clinic and holds a pharmacy license. It serves the medical and adult-use cannabis markets through retail and wholesale channels. The company is based in Stamford, Connecticut.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -78.21M | -113.36M | -124.37M | -226.43M | 64.80M |
| Minority interest | -2.92M | 6.58M | 9.14M | 6.83M | 7.40M |
| Net income | -273.36M | -238.17M | -281.20M | -370.10M | -101.73M |
| Selling general administrative | 458.07M | 438.60M | 434.78M | 475.56M | 415.74M |
| Gross profit | 631.02M | 640.78M | 614.45M | 579.03M | 687.59M |
| Reconciled depreciation | 216.04M | 248.02M | 211.91M | 176.47M | 132.64M |
| Ebit | - | - | - | - | 175.63M |
| Ebitda | - | - | - | 43.37M | 287.70M |
| Operating income | 25.45M | 24.74M | 42.88M | -12.37M | 175.63M |
| Interest expense | 100.83M | 100.62M | 100.38M | 93.33M | 90.26M |
| Tax provision | 123.69M | 98.25M | 114.59M | 150.50M | 173.93M |
| Interest income | 0.66M | 0.78M | 0.02M | 0.14M | 0.63M |
| Net interest income | -100.17M | -99.84M | -100.36M | -93.19M | -89.63M |
| Income tax expense | - | - | - | - | 173.93M |
| Total revenue | 1268.13M | 1334.30M | 1346.63M | 1336.34M | 1209.66M |
| Total operating expenses | 1242.68M | 1309.56M | 1303.75M | 1348.71M | 1034.03M |
| Cost of revenue | 637.11M | 693.52M | 732.18M | 757.31M | 522.07M |
| Total other income expense net | -3.50M | -38.26M | -66.89M | -120.86M | -21.20M |
| Net income from continuing ops | -244.20M | -234.35M | -238.96M | -376.93M | -109.13M |
| Net income applicable to common shares | - | - | - | - | -101.73M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 2845.32M | 2949.54M | 3096.58M | 3397.92M | 3262.48M |
| Intangible assets | 1011.12M | 1085.40M | 1172.44M | 1217.19M | 1010.01M |
| Other current assets | 37.38M | 28.13M | 30.40M | 32.30M | 80.58M |
| Total liab | 2005.03M | 1956.14M | 1925.28M | 1997.10M | 1453.99M |
| Total stockholder equity | 840.28M | 993.39M | 1171.29M | 1279.70M | 1757.26M |
| Other current liab | 19.93M | 20.07M | 28.11M | 41.34M | 179.82M |
| Common stock | - | - | - | - | 2225.94M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 2225.94M |
| Retained earnings | -1587.24M | -1356.17M | -1140.75M | -859.56M | -291.39M |
| Other liab | - | - | - | - | 406.19M |
| Good will | 635.12M | 628.88M | 626.63M | 625.13M | 605.50M |
| Other assets | - | - | - | - | 25.48M |
| Cash | 89.17M | 93.03M | 91.82M | 163.18M | 299.33M |
| Total current liabilities | 294.31M | 387.93M | 494.03M | 491.08M | 315.40M |
| Net debt | 459.48M | 475.59M | 495.95M | 459.64M | 136.76M |
| Short long term debt | 35.73M | 101.72M | 39.48M | 51.96M | 1.97M |
| Other stockholder equity | - | - | - | - | -172.08M |
| Property plant equipment | - | - | - | - | 664.83M |
| Total current assets | 448.62M | 429.68M | 418.60M | 605.33M | 952.26M |
| Long term investments | 0.26M | 14.98M | 2.48M | 2.80M | 4.40M |
| Net tangible assets | - | - | - | - | 141.75M |
| Net receivables | 73.86M | 63.99M | 60.00M | 52.16M | 66.89M |
| Long term debt | 512.92M | 466.90M | 548.29M | 570.86M | 434.12M |
| Inventory | 225.02M | 220.65M | 215.91M | 250.64M | 469.80M |
| Accounts payable | 74.72M | 79.13M | 79.32M | 85.26M | 26.75M |
| Non currrent assets other | 2.05M | 2.95M | 12.57M | 48.22M | 22.05M |
| Non current assets total | 2396.69M | 2519.86M | 2677.97M | 2792.59M | 2310.22M |
| Capital lease obligations | 278.31M | 285.20M | 295.78M | 309.09M | 317.56M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -0.17M | -0.71M | -0.71M | -228.62M | -163.97M |
| Change to liabilities | - | - | - | - | -10.30M |
| Total cashflows from investing activities | - | - | - | - | -163.97M |
| Net borrowings | -34.16M | -42.54M | -42.54M | - | 135.99M |
| Total cash from financing activities | -73.49M | -54.09M | -54.09M | 50.54M | 424.80M |
| Change to operating activities | - | - | - | - | -3.55M |
| Net income | -273.36M | -215.42M | -281.20M | -370.10M | -101.73M |
| Change in cash | -6.13M | 15.56M | 15.56M | -131.68M | 225.79M |
| Begin period cash flow | 107.23M | 91.82M | 91.82M | 299.33M | 73.54M |
| End period cash flow | 101.57M | 107.23M | 107.23M | - | 299.33M |
| Total cash from operating activities | 137.71M | 163.62M | 163.62M | 46.40M | -33.96M |
| Issuance of capital stock | - | 0.00M | 11.50M | 0.00M | 240.57M |
| Depreciation | 216.04M | 248.02M | 248.02M | 176.47M | 131.76M |
| Other cashflows from investing activities | - | - | - | - | 1.47M |
| Change to inventory | -3.72M | 4.31M | 4.31M | 31.24M | -105.19M |
| Change to account receivables | -10.96M | -7.79M | -7.79M | 7.96M | -29.40M |
| Other cashflows from financing activities | - | - | - | - | 53.40M |
| Change to netincome | - | - | - | - | 23.80M |
| Capital expenditures | 64.65M | 97.44M | 97.44M | 138.36M | 171.96M |
| Change in working capital | 120.39M | 105.49M | 105.49M | 110.21M | -88.68M |
| Stock based compensation | 35.74M | 25.70M | 25.70M | 28.02M | 45.63M |
| Other non cash items | 6.24M | 12.01M | 12.01M | 11.61M | -54.68M |
| Free cash flow | 73.06M | 66.19M | 66.19M | -91.96M | -205.92M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CURLF Curaleaf Holdings Inc |
-0.39 4.40% |
8.48 | - | 138.89 | 2.04 | 3.08 | 2.66 | 16.09 |
| MKKGY Merck KGaA ADR |
-0.74 2.19% |
33.06 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% |
170.05 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
0.34 1.66% |
21.18 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% |
41.72 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
Curaleaf Holdings, Inc. engages in the retail and wholesale of cannabis products in the United States and internationally. The company operates licensed cultivation; and pharma-grade cannabis processing and manufacturing facilities. It also supplies cannabis on a wholesale basis to Australia, New Zealand, the United Kingdom and various European countries, including Germany, Italy, Poland, the Czech Republic, Switzerland, Sweden and Norway. In addition, the company operates a medical cannabis clinic and holds a pharmacy license. It serves the medical and adult-use cannabis markets through retail and wholesale channels. The company is based in Stamford, Connecticut.
| Name | Title | Year Born |
|---|---|---|
| Mr. Boris Alexis Jordan | Exec. Chairman | 1966 |
| Mr. Joseph F. Lusardi | Exec. Vice-Chairman | 1974 |
| Mr. Joseph Daniel Bayern | Exec. Officer & Exec. of New Markets | 1963 |
| Mr. Matthew S. Darin | Chief Exec. Officer | NA |
| Mr. Edward Kremer | Chief Financial Officer | 1972 |
| Mr. Joe Holland | Exec. VP of Operations | NA |
| Mr. Camilo Russi Lyon | Chief Investment Officer | NA |
| Mr. Jakob Feinstein | Mang. of Investor Relations | NA |
| Mr. Peter Clateman J.D. | Chief Legal Officer | 1968 |
| Mr. James S. Shorris | Chief Compliance Officer | 1962 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.